Tiospirone

Tiospirone

SCHEMBL78696

O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2nsc3ccccc23)CC1

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tiospirone SCHEMBL29356145 1.00
Tiospirone SCHEMBL122406 0.99
SCHEMBL13532488 0.99
Tiospirone SCHEMBL11081111 0.98
SCHEMBL10471393 0.90 HTR1A (0.64)
SCHEMBL11077375 0.88 HTR1A (0.69)
SCHEMBL10520426 0.86
SCHEMBL10471021 0.86 HTR1A (0.61)
SCHEMBL11075546 0.86 HTR1A (0.66)
SCHEMBL9413636 0.86

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230414575-A1 MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS AKTTYVA THERAPEUTICS INC (US) 2023-12-28 US claimed
EP-4244341-A2 MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS Akttyva Therapeutics, Inc. (US) 2023-09-20 EP claimed
EP-4178948-A2 FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF Universidade de Santiago de Compostela (ES) 2023-05-17 EP claimed
WO-2023049482-A1 METHODS OF TREATING RESTRICTIVE EATING DISORDERS ARVID THERAPEUTICS (US) 2023-03-30 WO claimed
EP-1931320-B1 MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME FLAMEL IRELAND LTD (IE) 2022-06-15 EP claimed
WO-2022104097-A2 MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS AKTTYVA THERAPEUTICS, INC. (US) 2022-05-19 WO claimed
EP-3956025-A1 CGRP ANTAGONISTS FOR THE TREATMENT OF MEDICATION OVERUSE HEADACHE, POST-TRAUMATIC HEADACHE, POST-CONCUSSION SYNDROME AND VERTIGO Allergan Sales, LLC (US) 2022-02-23 EP claimed
WO-2022023496-A2 FUNCTIONALIZED ISONITRILES AND PRODUCTS, PREPARATION AND USES THEREOF UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) 2022-02-03 WO claimed
US-20210228488-A1 EXTENDED RELEASE COMPOSITIONS AND PROCESS FOR PREPARATION RUBICON RES PRIVATE LIMITED (IN) 2021-07-29 US claimed
EP-3817766-A2 COMBINATION THERAPY WITH CGRP ANTAGONISTS AND CLOSTRIDIAL DERIVATIVES Allergan Pharmaceuticals International Limited (IE) 2021-05-12 EP claimed
EP-1238676-A1 Combination of a serotonin reuptake inhibitor and an atypical antipsychotic for use in depression, obsessive compulsive disorder and psychosis Pfizer Products Inc. (US) 2002-09-11 EP claimed
US-20020123490-A1 Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis PFIZER INC. 2002-09-05 US claimed
EP-0539059-B1 Buoyant controlled release powder formulation SQUIBB & SONS INC (US) 1997-12-17 EP claimed
EP-0573581-A4 COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN ARC 1 INC (US) 1994-06-29 EP claimed
EP-0573581-A1 COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN ARC 1, Inc. (US) 1993-12-15 EP claimed
EP-0539059-A1 Buoyant controlled release powder formulation E.R. SQUIBB & SONS, INC. (US) 1993-04-28 EP claimed
US-5169638-A Powder filled capsules E. R. SQUIBB & SONS, INC. (US) 1992-12-08 US claimed
WO-1992014453-A1 COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN ARC 1, INC. (US) 1992-09-03 WO claimed
US-4847252-A Method for alleviation of vascular headache BRISTOL-MYERS COMPANY (US) 1989-07-11 US claimed
US-4411901-A ANTIPSYCHOTICS MEAD JOHNSON & COMPANY (US) 1983-10-25 US claimed